Trade Gilead Sciences Inc - GILD CFD

Add to favourite

92.59

1.92%

0.36

Low: 89.95

High: 93.19

Market Trading Hours* (UTC) Opens on Monday at 09:00

Mon: 09:00 - 00:00

Tue: 00:00 - 01:00 09:00 - 18:00

Thu: 09:00 - 00:00

Fri: 00:00 - 01:00 09:00 - 22:00

Summary
Historical Data

Trading сonditions

Spread

0.36

Long position overnight fee

-0.023374%

Short position overnight fee

0.001151%

Overnight fee time

22:00 (UTC)

Min traded quantity

0.1

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	90.85
Open	90.85
1-Year Change	14.74%
Day's Range	89.95 - 93.19

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Dec 20, 2024	92.59	1.74	1.92%	90.85	93.23	89.79
Dec 19, 2024	90.85	0.70	0.78%	90.15	91.39	89.95
Dec 18, 2024	90.15	-2.42	-2.61%	92.57	93.39	90.15
Dec 17, 2024	92.27	0.65	0.71%	91.62	93.51	90.35
Dec 16, 2024	90.95	-0.04	-0.04%	90.99	93.20	90.85
Dec 13, 2024	91.90	0.30	0.33%	91.60	92.06	89.08
Dec 12, 2024	91.60	-0.35	-0.38%	91.95	93.16	90.85
Dec 11, 2024	91.95	-0.30	-0.33%	92.25	94.57	90.85
Dec 10, 2024	92.43	1.97	2.18%	90.46	92.88	89.46
Dec 9, 2024	90.23	-1.43	-1.56%	91.66	92.07	90.23
Dec 6, 2024	91.71	-1.04	-1.12%	92.75	94.10	91.65
Dec 5, 2024	92.75	1.60	1.76%	91.15	94.20	90.67
Dec 4, 2024	90.95	-1.07	-1.16%	92.02	92.48	89.77
Dec 3, 2024	92.40	-1.56	-1.66%	93.96	94.36	91.95
Dec 2, 2024	93.96	2.07	2.25%	91.89	94.30	91.89
Nov 29, 2024	92.51	-1.19	-1.27%	93.70	94.08	92.05
Nov 28, 2024	92.83	0.00	0.00%	92.83	92.83	92.83
Nov 27, 2024	92.35	1.01	1.11%	91.34	92.84	90.95
Nov 26, 2024	90.99	1.53	1.71%	89.46	91.59	89.00
Nov 25, 2024	89.42	-0.43	-0.48%	89.85	91.27	89.42

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Gilead Company profile

What is Gilead Sciences?

Gilead Sciences Inc. is a US biopharmaceutical company. Following a series of mergers and acquisitions, Gilead is now one of the biggest players in its field with almost 9,000 employees working all over the globe. A portfolio of shipped products includes medicals for HIV treatment and HIV prevention. Gilead focuses on medical products that serve to cure oncology, liver diseases, cardiovascular disorders and many other severe health conditions. Gilead has a wide network of partnerships and collaborations.

What does the company do?

A research-based biopharmaceutical company, Gilead Sciences, discovers, produces and markets innovative healthcare products that are capable of transforming and simplifying medical care for people, who suffer from life-threatening diseases globally.

The portfolio of Gilead’s products and investigational drugs includes innovative treatments for AIDS/HIV, cancer, respiratory, inflammatory, liver diseases and cardiovascular conditions.

A bit of Gilead Sciences’ history

Gilead Sciences was established in June 1987. The company primarily focused on antiviral medicines. It concentrated on gene therapy, estimating the potential of genetic code blockers. The development and research of small molecule antiviral therapeutics started in 1991 with licensing of a group of nucleotide compounds (tenofovir was one of them) that further became widely-used anti-retroviral medicines. In 1990, Gilead collaborated with Glaxo for the development and research of genetic code blockers, known as antisense.

Who founded Gilead Sciences?

Gilead Sciences was founded by Michael L. Riordan, a 29-year-old doctor, who graduated from the Johns Hopkins School of Medicine, Washington University of St. Louis and the Harvard Business School. Riordan worked as the company’s CEO from its inception till 1996.

Establishing the company and its vision, Michael L. Riordan collaborated with three major scientific advisors, including Doug Melton of Harvard, Peter Dervan of Caltech and Harold Weintraub of the Fred Hutchinson Cancer Research Center.

A venture capital firm Menlo Ventures, where Riordan worked for one year, made the first investment of $2 million into Gilead Sciences.

Current size, team and locations

Headquartered in Foster City, California, US, the company operates across 6 continents and has a team of almost 9,000 employees. Gilead has a portfolio of 24 marketed products and is rapidly expanding. The research and development division works on over 400 clinical studies, evaluating compounds that potentially will become the next generation of efficient medicines.

Quick facts about Gilead Sciences

Developing access programmes to provide HIV and viral hepatitis medicines at significantly reduced prices in 134 low- and middle-income countries, the company serves approximately 10 million people in the developing world with Gilead’s HIV/AIDS therapies.
It is said that Riordan wanted to attract Warren Buffett as Gilead’s board member and investor, but was unsuccessful.
In 2005 the company created the Gilead Foundation, a non-profit organisation that is trying to improve the well-being and health of underserved communities in the United States and globally.
In 2016 the company gained $30.4 billion in revenue and was ranked the second in the Barron’s 500 rankings. The company also became the first in Business Insider’s list of top companies to work for.

How to learn the Gilead Sciences share price?

Gilead Sciences shares are listed and traded on the NASDAQ stock exchange under the ticker symbol GILD. The company is a component of the US Tech 100, S&P 500 and S&P 100 indices. Join Capital.com to trade CFDs on the Gilead Sciences share price fluctuations and follow the GILD chart in real-time.

Industry:

Pharmaceuticals (NEC)

333 Lakeside Dr
FOSTER CITY
CALIFORNIA 94404-1147
US

News

Pi Network coin price prediction: Third party price target

Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com

13:51, 13 December 2024

Euro forecast: third party data roundup

In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.

22:39, 12 December 2024

Projected US interest rates in 5 years: Third party round up

As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?

14:28, 12 December 2024

Street in City of London with Royal Exchange, Bank of England and new modern skyscrapers

Projected UK interest rates in 5 years

Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?

11:20, 12 December 2024